Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Like other GLP-1 receptor agonists used for treatment of type 2 diabetes, liraglutide delays gastric emptying. In this clinical absorption study, the primary objective was to investigate the effect of liraglutide (at steady state) on the rate and/or extent of gastrointestinal (GI) absorption of concomitantly orally taken drugs from three classes of the Biopharmaceutics Classification System (BCS). To provide a general prediction on liraglutide drug-drug absorption interaction, single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at steady state of liraglutide 1.8 mg, or placebo, in a two-period crossover design. With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%); griseofulvin had similar tmax and 37% increased Cmax. Although the prespecified bioequivalence criterion was not met by all drugs, the overall plasma exposure (AUC) of griseofulvin, atorvastatin, lisinopril, and digoxin only exhibited minor changes and was not considered to be of clinical relevance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PK data on ACEI and GLP1 agonist co-treatment showed different effects by different GLP1RAs (Table 3); Still, all changes were interpreted as minor and non-clinically significant [23, 24, 30, 32, 38].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
In the citing paper
“Liraglutide was an exception as it also decreased the AUC [24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
In the citing paper
“The PK studies with lixisenatide [36], liraglutide [24] and semaglutide [16, 27] demonstrated reduced Cmax and delayed tmax of atorvastatin, but overall minor changes in the AUC were not considered to be of clinical importance (Table 3).”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Self-citationWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Self-citationDigoxin intoxication: the relationship of clinical presentation to serum digoxin concentration
Smith, T. W., & Haber, E. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106457 · Cited by 336
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Self-citationSchjoldager, B. T. G., Mortensen, P. E., Christiansen, J., �rskov, C., & Holst, J. J. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540341 · Cited by 178
Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
Glucagon-like peptide-1 (7–36)-NH2: a physiological inhibitor of gastric acid secretion in man
O'Halloran, D. J., Nikou, G. C., Kreymann, B., Ghatei, M. A., & Bloom, S. R. (1990) · Journal of Endocrinology · doi:10.1677/joe.0.1260169 · Cited by 91
Cited by
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“These effects were not considered to be clinically relevant [44, 53, 54] and dose adjustments for co-administered drugs are not required [18, 19].”
BackgroundAn updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 188
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 206
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“140,147,153,155,159 However, statins are known to exhibit high interindividual variability in terms of pharmacokinetics, and GLP-1 RA administration did not affect the lipid-lowering effect of statins in clinical studies, indicating minimal clinical significance.”
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Liraglutide was an exception as it also decreased the AUC [24].”
BackgroundInfluentialBækdal, T. A., Borregaard, J., Hansen, C. W., Thomsen, M., & Anderson, T. W. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00756-2 · Cited by 63
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
“In general, these findings confirm that semaglutide has a minor effect on the absorption of the drugs investigated, a group of drugs with various degrees of solubility, permeability and narrow therapeutic windows, and are consistent with results from previous studies with GLP-1RAs [31, 37–40].”
BackgroundResultInfluentialMorse, B. L., Alberts, J. J., Posada, M. M., Rehmel, J., Kolur, A., Tham, L. S., Loghin, C., Hillgren, K. M., Hall, S. D., & Dickinson, G. L. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12447 · Cited by 35
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
“This effect is seen in combination therapy of liraglutide with griseofulvin (47).”
BackgroundBellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 17
Cope, R. J., Fischetti, B., Kavanagh, R., Lepa, T. M., & Sorbera, M. A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2342 · Cited by 17
Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Langeskov, E. K., & Kristensen, K. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.962 · Cited by 12
Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists
Maideen, N. M. P. (2019) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2019.08.00311 · Cited by 14
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
GLP ‐1 agonists for people living with HIV and obesity, is there a potential?
Zino, L., Tack, C. J., Richel, O., & Burger, D. M. (2023) · HIV Medicine · doi:10.1111/hiv.13521 · Cited by 14
“GLP-1 agonists are known to inhibit gastric acid secretion and to delay gastric emptying in humans [38].”
BackgroundPaggers, L., Mesotten, D., & Stragier, H. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002103 · Cited by 8
Maslub, M. G., Daud, N. A. A., Radwan, M. A., Sha’aban, A., & Ibrahim, A. G. (2024) · European journal of medical research · doi:10.1186/s40001-024-02109-7 · Cited by 10
“Atorvastatin CL/F decreased to half (P < 0.05), and CL decreased to less than half (P < 0.05) of what was observed in Swedes [67].”
ResultInfluentialGu, Y., Yao, L., Jiang, T., & Che, H. (2022) · Foods · doi:10.3390/foods11233758 · Cited by 5
Bogman, K., Brumm, J., Hofmann, C., Giraudon, M., Niggli, M., Sturm, C., Sauter, A., Sturm, S., Mangold, B., & Schmitt, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00757-1 · Cited by 5
Yang, Y., Wang, Y., & Du, C. (2025) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2025.107474 · Cited by 4
Wu, X., He, J., Wu, J., Liu, W., Xu, Y., Li, Y., Zhang, J., & Wang, Q. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01541-0 · Cited by 4
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer
Giraud, E. L., Krens, S. D., Böhringer, S., Desar, I. M. E., Vermeulen, S. H. H. M., Kiemeney, L. A. L. M., Huitema, A. D. R., Steeghs, N., van Erp, N. P., & Swen, J. J. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16196 · Cited by 6
“34 Based on these results, the involvement of GLP1R in changes in the PK of sunitinib remains unclear, yet a possible association between GLP-1(R) and high sunitinib exposure cannot be ruled out.”
The roles of bitter and sweet taste receptors in food allergy: Where are we now?
Xian, M., Maskey, A., Kopulos, D., & Li, X.-M. (2025) · Allergology International · doi:10.1016/j.alit.2025.01.005 · Cited by 5
Posada, M. M., Schneck, K. B., Morse, B. L., Rougée, L. R. A., Tham, L. S., Rehmel, J., Thompson, B., Stamatis, S. D., Hall, S. D., & Dickinson, G. L. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70101 · Cited by 4
“The expected influence of gastric emptying delay on drug absorption can be examined through the lens of the biopharmaceutical classification system [13], as this is a good initial approach and has been used previously [8].”
InfluentialSaiti, A., Giannopoulos‐Dimitriou, A., Kazakos, I., Galatou, E., & Vizirianakis, I. S. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010021 · Cited by 5
HIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2024) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“However, AUC changed only minimally for all four drugs and was not considered clinically relevant [146].”
Ness, A., Levi, Z., Belfer, R. G., Dickman, R. M., & Boltin, D. (2025) · Helicobacter · doi:10.1111/hel.70014 · Cited by 3
Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists
Maideen, N. M. P. (2019) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2019.08.00310 · Cited by 7
Robins, D., Lehmann, A., Krollik, K., & Vertzoni, M. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106881 · Cited by 1
Morse, B. L., Ma, X., Liu, R., Bhattachar, S., Nicoll, C., Varghese, N. M., Kelly, R. P., Stamatis, S. D., & Pratt, E. J. (2025) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-025-00937-4 · Cited by 1
“This fed state-induced delay in t max and decrease in C max are consistent with previous reports on agents that delay gastric emptying [19, 33].”
INTERACCIONES FARMACOLÓGICAS DE ESTATINAS CON AGENTES ANTIDIABÉTICOS NO INSULÍNICOS
Cordo, C. S., Salzberg, S., Alvariñas, J., Cean, P., Folino, C., Bragagnolo, J. C., Dagum, A., Frechtel, G. D., & Serra, A. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v51i2.68
Еременко, Н. Н. (2025) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2025-13-1-86-93
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
Poloni, A., Cattaneo, D., Giacomelli, A., Gori, A., Ridolfo, A. L., & Gervasoni, C. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf245
Li, F., Du, C., Yu, Q., Feng, S., Cai, L., Chen, Z. X., Zou, Q., Guo, W., Du, D., Hu, F., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70880
“…with other GLP-1 RA show variability: Coadministration with liraglutide injection reduced digoxin AUC and C max by 16% and 31%, respectively [19]; coadministration with albiglutide resulted in no change in AUC but an 11% increase in C max [20] and coadministration with semaglutide showed no…”
An Overlooked Impact of GLP-1 Receptor Agonists on Enteric Coated Medications
Atef, E., & Elkeeb, R. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000030
Metadata
- Authors
- Malm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- IQVIA (United States) (US)
- Uppsala University (SE)
- Corresponding author
- Malm-Erjefält, Monika
- ORCID
- Lennernäs, Hans
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-10-12
- Volume
- 12
- Issue
- 11
- Pages
- 4166-4173
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2403796176
- Cited by
- 36
- References
- 25
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 1 · 2017: 1 · 2015: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, gastrointestinal drug absorption, drug-drug interactions, Biopharmaceutics Classification System, GLP-1 receptor agonists, gastric emptying, atorvastatin, griseofulvin, lisinopril, digoxin, bioequivalence, pharmacokinetics, type 2 diabetes
- MeSH terms
- Atorvastatin, Liraglutide, Administration, Oral, Adolescent, Adult, Antifungal Agents, Antihypertensive Agents, Biopharmaceutics, Cardiotonic Agents, Computer Simulation, Digoxin, Double-Blind Method, Drug Interactions, Female, Gastric Emptying, Griseofulvin, Humans, Hypoglycemic Agents, Male, Middle Aged, Therapeutic Equivalency, Tissue Distribution, Lisinopril, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult, Gastrointestinal Absorption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.